Valérie Anne McLin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Valérie Anne McLin has a total of 546 co-authors. Here are the top co-authors by number of shared publications:
- Barbara Elisabeth Wildhaber
Division of Pediatric Surgery, Department of Pediatrics, Gynecology and Obstetrics, University Hospitals of Geneva, University of Geneva, 1205 Geneva, Switzerland
9 shared publications - Nathalie Rock
Pediatric Gastroenterology, Hepatology and Nutrition Unit, Division of Pediatric Specialties, Department of Pediatrics, Gynecology and Obstetrics, Swiss Pediatric Liver Center, University Hospitals of Geneva, University of Geneva
7 shared publications - Anne-Laure Rougemont
Pediatric and Fetoplacental Pathology Unit, Division of Clinical Pathology, Diagnostic Department Geneva University Hospitals and Faculty of Medicine, University of Geneva Geneva Switzerland
6 shared publications - Lorenzo D’ Antiga
Pediatric Hepatology, Gastroenterology and Transplantation, ASST Papa Giovanni XXIII Bergamo Italy
6 shared publications - Dominique Debray
Pediatric Hepatology Unit, Necker Hospital, Paris, France
5 shared publications - Klara Maria Posfay-Barbe
Faculty of Medicine, University of Geneva, Geneva, Switzerland
5 shared publications
Latest Publications
- Open Access
Genetic hallmarks of patients with congenital portosystemic shunts and portopulmonary hypertension: protocol for a multicentre exploratory study
Introduction: Congenital portosystemic shunts (CPSS) are rare vascular malformations, with an estimated prevalence of 1/30’000 live births, that cause portal blood to partly bypass the liver. CPSS frequently co-occur with congenital heart disease and other malformations, suggesting a shared developmental or genetic basis. Severe acquired clinical manifestations are present in a large proportion of patients with CPSS. Portopulmonary hypertension (PoPH), the most life-threatening, has been reported in as many as 7–14% of CPSS patients. Mounting evidence indicates that PoPH can arise early in life, particularly in children with CPSS, yet paediatric PoPH remains understudied. This project aims to identify genetic variants associated with PoPH in CPSS patients through whole-genomes, focusing primarily on known pathogenic genes for pulmonary arterial hypertension (PAH), congenital heart disease (CHD), Hereditary Haemorrhagic Telangiectasia (HHT), SNPs previously associated with PoPH in adults, and ultimately novel genomic variants. The overarching goal of the study is to improve personalised risk assessment and inform clinical decisions regarding elective shunt closure in individuals potentially at-risk of developing PoPH. Methods and analysis: The aim is to perform an international multi-centre exploratory genome analysis of patients with CPSS and PoPH identified through the International Registry of Congenital Portosystemic Shunts (IRCPSS). Whole-genome sequencing will be utilized to analyse both coding and non-coding regions in a predominantly paediatric cohort. Targeted analysis of established pathogenic genes associated with PAH, CHD, HHT, and PoPH will be complemented by a genome-wide approach to identify novel, potentially pathogenic variants, with variant classification assessed according to American College of Medical Genetics (ACMG) criteria. Family-based analyses, including trio analyses and segregation studies, will enable the identification of dominant, recessive, and de novo variants, facilitating a comprehensive evaluation of variant inheritance pattern and pathogenic potential. Ethics and dissemination: This study has been approved by the CCER (Geneva cantonal ethics committee for research) and poses minimal risk to participants, limited to blood sampling performed as part of routine clinical care for patients. Genetic data will be securely stored and analysed in compliance with GDPR. Clinically significant findings will be communicated through recruiting physicians, in accordance with participant preference regarding incidental findings. Study results will be disseminated through open-access peer-reviewed publications and scientific conferences to advance understanding and management of PoPH in individuals with CPSS and potentially other chronic liver diseases associated with portosystemic bypass. ClinicalTrials.gov: NCT07314814 CCER Ethical approval: 2024-01698 STRENGTHS AND LIMITATIONS OF THIS STUDY: Systematic analysis of established gene panels for PAH, CHD and HHT, to diagnose referenced genetic disorders. The trio-based whole-genome analysis design allows for the detection of novel potentially pathogenic variants and genes. The rarity of CPSS limits recruitment to an expected sample size of ~30 trios, both a realistic target for a rare disease study and appropriate family-based analyses. Leverages the International Registry of Congenital Portosystemic Shunts as a resource for correlating genetic and clinical data
Open AccessGenetic hallmarks of patients with congenital portosystemic shunts and portopulmonary hypertension: protocol for a multicentre exploratory study
Introduction: Congenital portosystemic shunts (CPSS) are rare vascular malformations, with an estimated prevalence of 1/30’000 live births, that cause portal blood to partly bypass the liver. CPSS frequently co-occur with congenital heart disease and other malformations, suggesting a shared developmental or genetic basis. Severe acquired clinical manifestations are present in a large proportion of patients with CPSS. Portopulmonary hypertension (PoPH), the most life-threatening, has been reported in as many as 7–14% of CPSS patients. Mounting evidence indicates that PoPH can arise early in life, particularly in children with CPSS, yet paediatric PoPH remains understudied. This project aims to identify genetic variants associated with PoPH in CPSS patients through whole-genomes, focusing primarily on known pathogenic genes for pulmonary arterial hypertension (PAH), congenital heart disease (CHD), Hereditary Haemorrhagic Telangiectasia (HHT), SNPs previously associated with PoPH in adults, and ultimately novel genomic variants. The overarching goal of the study is to improve personalised risk assessment and inform clinical decisions regarding elective shunt closure in individuals potentially at-risk of developing PoPH. Methods and analysis: The aim is to perform an international multi-centre exploratory genome analysis of patients with CPSS and PoPH identified through the International Registry of Congenital Portosystemic Shunts (IRCPSS). Whole-genome sequencing will be utilized to analyse both coding and non-coding regions in a predominantly paediatric cohort. Targeted analysis of established pathogenic genes associated with PAH, CHD, HHT, and PoPH will be complemented by a genome-wide approach to identify novel, potentially pathogenic variants, with variant classification assessed according to American College of Medical Genetics (ACMG) criteria. Family-based analyses, including trio analyses and segregation studies, will enable the identification of dominant, recessive, and de novo variants, facilitating a comprehensive evaluation of variant inheritance pattern and pathogenic potential. Ethics and dissemination: This study has been approved by the CCER (Geneva cantonal ethics committee for research) and poses minimal risk to participants, limited to blood sampling performed as part of routine clinical care for patients. Genetic data will be securely stored and analysed in compliance with GDPR. Clinically significant findings will be communicated through recruiting physicians, in accordance with participant preference regarding incidental findings. Study results will be disseminated through open-access peer-reviewed publications and scientific conferences to advance understanding and management of PoPH in individuals with CPSS and potentially other chronic liver diseases associated with portosystemic bypass. ClinicalTrials.gov: NCT07314814 CCER Ethical approval: 2024-01698 STRENGTHS AND LIMITATIONS OF THIS STUDY: Systematic analysis of established gene panels for PAH, CHD and HHT, to diagnose referenced genetic disorders. The trio-based whole-genome analysis design allows for the detection of novel potentially pathogenic variants and genes. The rarity of CPSS limits recruitment to an expected sample size of ~30 trios, both a realistic target for a rare disease study and appropriate family-based analyses. Leverages the International Registry of Congenital Portosystemic Shunts as a resource for correlating genetic and clinical data
- Open Access
- 11 September 2026
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 41 (1) , 215
Differential metabolic and cellular brain regional susceptibility in adult rats with chronic liver disease
- 11 September 2026
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 41 (1) , 215
Open AccessDifferential metabolic and cellular brain regional susceptibility in adult rats with chronic liver disease
- Top Cited PapersOpen Access
- 26 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (10) , 3733-3743
Long-term MAPK inhibition of childhood refractory-Langerhans cell histiocytosis: an observational study of 288 patients
We evaluated long-term outcomes of 288 children with refractory-Langerhans cell histiocytosis (R-LCH) from 26 countries, who were prescribed off-label MAPK inhibitors (MAPKis) according to clinical indications. MAPKi indications included 148 R-risk-organ–positive (R-RO+), 67 R-risk-organ–negative (R-RO–), 13 lung destruction (lung), 9 sclerosing cholangitis (SC), 49 neurodegeneration (ND), and 2 diabetes insipidus (DI) cases. Median ages at diagnosis and MAPKi onset were 1.3 and 2.3 years, respectively, with median follow-up of 3.7 years (1166 person-years). Agents mostly prescribed as monotherapies were 184 prescriptions of vemurafenib, 115 of dabrafenib, 3 of encorafenib, 42 of cobimetinib, 45 of trametinib, and/or 1 prescription of binimetinib; followed 51 times by various chemotherapies or hematopoietic stem-cell transplantation, or 28 times by combined anti-BRAF–anti-MEK. Short-term responses (<8 weeks) ranged from 98% (R-RO+ and R-RO–), to 30% (lung) to none (ND, DI, and SC); although long-term lung and ND responses could be observed. Skin rash was the most frequent adverse event (∼55%), and 7 others included 1 case of cardiomyopathy and 6 of retinitis. Five developed MAPKi-unrelated tumors and 9 patients died. Five-year survival was 98%. After 113 patients with R-LCH discontinued MAPKi, 69 experienced disease reactivation. None of the various empirical maintenance therapies were able to prevent secondary reactivation. Among the 143 assessable patients without ND-LCH at MAPKi onset, 60 developed ND (45%, 5-year risk). MAPKis appeared to be safe and effective in children with R-RO+/RO–LCH, whereas other indications’ responses were less frequent or occurred later. Further studies are needed to find effective maintenance-therapy approaches, particularly to prevent frequently observed secondary ND.
- 26 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (10) , 3733-3743
Top Cited PapersOpen AccessLong-term MAPK inhibition of childhood refractory-Langerhans cell histiocytosis: an observational study of 288 patients
We evaluated long-term outcomes of 288 children with refractory-Langerhans cell histiocytosis (R-LCH) from 26 countries, who were prescribed off-label MAPK inhibitors (MAPKis) according to clinical indications. MAPKi indications included 148 R-risk-organ–positive (R-RO+), 67 R-risk-organ–negative (R-RO–), 13 lung destruction (lung), 9 sclerosing cholangitis (SC), 49 neurodegeneration (ND), and 2 diabetes insipidus (DI) cases. Median ages at diagnosis and MAPKi onset were 1.3 and 2.3 years, respectively, with median follow-up of 3.7 years (1166 person-years). Agents mostly prescribed as monotherapies were 184 prescriptions of vemurafenib, 115 of dabrafenib, 3 of encorafenib, 42 of cobimetinib, 45 of trametinib, and/or 1 prescription of binimetinib; followed 51 times by various chemotherapies or hematopoietic stem-cell transplantation, or 28 times by combined anti-BRAF–anti-MEK. Short-term responses (<8 weeks) ranged from 98% (R-RO+ and R-RO–), to 30% (lung) to none (ND, DI, and SC); although long-term lung and ND responses could be observed. Skin rash was the most frequent adverse event (∼55%), and 7 others included 1 case of cardiomyopathy and 6 of retinitis. Five developed MAPKi-unrelated tumors and 9 patients died. Five-year survival was 98%. After 113 patients with R-LCH discontinued MAPKi, 69 experienced disease reactivation. None of the various empirical maintenance therapies were able to prevent secondary reactivation. Among the 143 assessable patients without ND-LCH at MAPKi onset, 60 developed ND (45%, 5-year risk). MAPKis appeared to be safe and effective in children with R-RO+/RO–LCH, whereas other indications’ responses were less frequent or occurred later. Further studies are needed to find effective maintenance-therapy approaches, particularly to prevent frequently observed secondary ND.
- Open Access
- 14 April 2026
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (7) , 991-1003
Preformed donor-specific antibodies are associated with acute rejection and biliary complications after liver transplantation: A Swiss Transplant Cohort Study analysis
The impact of preformed donor-specific antibodies (DSA) in liver transplantation (LT) remains controversial despite evidence linking their presence to an increased risk of early allograft damage, as well as antibody- and T-cell–mediated rejection. In this nationwide analysis, preformed DSA were assessed using single-antigen bead assays [positive if mean fluorescence intensity (MFI) ≥1000]. This study included all LT recipients enrolled in the Swiss Transplant Cohort Study (STCS) who underwent LT between 2014 and 2016. One-year post-LT outcomes, including cumulative allograft and patient survival, as well as the incidence of biliary, vascular, and infectious complications, were compared between DSA-positive (DSA+) and DSA-negative (DSA−) individuals. Among 321 LT performed in 306 patients, preformed DSA were detected in 92 (28.7%) and more frequently observed in patients with a history of prior transplantation ( p =0.008) or autoimmune liver disease ( p =0.036). Class I and II DSA were present in 48.9% and 71.1% of DSA+ cases, with concomitant class I and II DSA in 20.7%. The median (IQR) cumulative MFI (cMFI) of the preformed DSA was 3768 (1875–10,537), and 52.2% of DSA+ patients harbored multiple DSA. While overall patient survival did not differ between DSA+ and DSA− individuals, DSA+ patients with cMFI ≥5000 exhibited a higher incidence of allograft failure and biopsy-proven rejection. Multivariate analysis revealed that the presence of preformed DSA was independently associated with biliary complications (HR 2.26, 95% CI 1.17–4.37, p =0.02) but not with vascular or infectious complications. In summary, preformed DSA were associated with biliary complications, increased rejection, and reduced allograft survival. These findings suggest pre-transplant immunological risk assessment and the need for tailored immunosuppressive strategies in LT.
- 14 April 2026
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (7) , 991-1003
Open AccessPreformed donor-specific antibodies are associated with acute rejection and biliary complications after liver transplantation: A Swiss Transplant Cohort Study analysis
The impact of preformed donor-specific antibodies (DSA) in liver transplantation (LT) remains controversial despite evidence linking their presence to an increased risk of early allograft damage, as well as antibody- and T-cell–mediated rejection. In this nationwide analysis, preformed DSA were assessed using single-antigen bead assays [positive if mean fluorescence intensity (MFI) ≥1000]. This study included all LT recipients enrolled in the Swiss Transplant Cohort Study (STCS) who underwent LT between 2014 and 2016. One-year post-LT outcomes, including cumulative allograft and patient survival, as well as the incidence of biliary, vascular, and infectious complications, were compared between DSA-positive (DSA+) and DSA-negative (DSA−) individuals. Among 321 LT performed in 306 patients, preformed DSA were detected in 92 (28.7%) and more frequently observed in patients with a history of prior transplantation ( p =0.008) or autoimmune liver disease ( p =0.036). Class I and II DSA were present in 48.9% and 71.1% of DSA+ cases, with concomitant class I and II DSA in 20.7%. The median (IQR) cumulative MFI (cMFI) of the preformed DSA was 3768 (1875–10,537), and 52.2% of DSA+ patients harbored multiple DSA. While overall patient survival did not differ between DSA+ and DSA− individuals, DSA+ patients with cMFI ≥5000 exhibited a higher incidence of allograft failure and biopsy-proven rejection. Multivariate analysis revealed that the presence of preformed DSA was independently associated with biliary complications (HR 2.26, 95% CI 1.17–4.37, p =0.02) but not with vascular or infectious complications. In summary, preformed DSA were associated with biliary complications, increased rejection, and reduced allograft survival. These findings suggest pre-transplant immunological risk assessment and the need for tailored immunosuppressive strategies in LT.
- Open Access
- 29 April 2025
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 11 (5) , e1787
Pediatric Liver and Kidney Transplant Recipients Demonstrate Greater Serological Response to SARS-CoV-2 Vaccination Than Adults
Background.: Adult solid organ transplant recipients (SOTRs) have decreased responsiveness to severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) vaccination and higher incidence of infection, but there are few data on the serological response in pediatric SOTR. The aim of this study was to determine serological response to SARS-CoV-2 vaccination in pediatric liver (LT) and kidney transplant (KT) recipients and compare it with adult SOTR. Methods.: A European, prospective, multicenter study was performed. Samples were taken at 7 and 32 wk following COVID-19 vaccination and serological endpoints were measured by ELISA. Results.: A total of 42 pediatric (16 post-LT and 26 post-KT) and 117 adult (all post-LT) were included. All pediatric participants and 94% adult participants received mRNA vaccines. Paediatric SOTR patients had significantly higher anti-Spike IgG levels than adult participants at week 7 (114 220.7 [59 285.92–220 058.55] versus 8756.7 [5643.69–13 586.71], P < 0.0001) and week 32 (46 113.2 [10 992.91–193 436.14] versus 8207.0 [3561.20–18 913.43], P = 0.0032). No significant difference in week 7 anti-Spike IgG response was found between pediatric LT and KT (129 434.4 [51 888.64–322 869.69] versus 105 304.5 [39 910.20–277 849.50], P = 0.9854). No differences were seen between children and adults in the rate of decline of anti-Spike IgG between weeks 7 and 32 (P = 0.8000). Male sex and hemolytic-uremic syndrome or postischemic kidney disease were associated with lower anti-Spike IgG levels at week 7 in pediatric SOTR. Conclusions.: Paediatric SOTR demonstrate greater SARS-CoV-2 vaccine responses than comparable adult SOTR patients. These data support efficacy and safety of SARS-CoV-2 vaccination in child SOTR and may alleviate vaccine hesitancy in this patient group.
- 29 April 2025
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 11 (5) , e1787
Open AccessPediatric Liver and Kidney Transplant Recipients Demonstrate Greater Serological Response to SARS-CoV-2 Vaccination Than Adults
Background.: Adult solid organ transplant recipients (SOTRs) have decreased responsiveness to severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) vaccination and higher incidence of infection, but there are few data on the serological response in pediatric SOTR. The aim of this study was to determine serological response to SARS-CoV-2 vaccination in pediatric liver (LT) and kidney transplant (KT) recipients and compare it with adult SOTR. Methods.: A European, prospective, multicenter study was performed. Samples were taken at 7 and 32 wk following COVID-19 vaccination and serological endpoints were measured by ELISA. Results.: A total of 42 pediatric (16 post-LT and 26 post-KT) and 117 adult (all post-LT) were included. All pediatric participants and 94% adult participants received mRNA vaccines. Paediatric SOTR patients had significantly higher anti-Spike IgG levels than adult participants at week 7 (114 220.7 [59 285.92–220 058.55] versus 8756.7 [5643.69–13 586.71], P < 0.0001) and week 32 (46 113.2 [10 992.91–193 436.14] versus 8207.0 [3561.20–18 913.43], P = 0.0032). No significant difference in week 7 anti-Spike IgG response was found between pediatric LT and KT (129 434.4 [51 888.64–322 869.69] versus 105 304.5 [39 910.20–277 849.50], P = 0.9854). No differences were seen between children and adults in the rate of decline of anti-Spike IgG between weeks 7 and 32 (P = 0.8000). Male sex and hemolytic-uremic syndrome or postischemic kidney disease were associated with lower anti-Spike IgG levels at week 7 in pediatric SOTR. Conclusions.: Paediatric SOTR demonstrate greater SARS-CoV-2 vaccine responses than comparable adult SOTR patients. These data support efficacy and safety of SARS-CoV-2 vaccination in child SOTR and may alleviate vaccine hesitancy in this patient group.
- Open Access
- 16 April 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (3) , e70060
Meeting the Challenges of Post‐Transplant Lymphoproliferative Disorders After Liver Transplantation in Children: A Proposed Diagnostic and Management Algorithm
Background: Post‐transplant lymphoproliferative disorders (PTLD) may significantly impair outcomes in children after solid organ transplantation (SOT). Diagnosis and treatment may be challenging. We analyze a representative pediatric liver transplant (LT) cohort in light of these challenges.Methods: Pediatric LT recipients monitored by the Swiss Pediatric Liver Center from 2009 to 2021 with a suspicion of Epstein–Barr virus (EBV) driven PTLD were included. All cases were retrospectively reviewed using the World Health Organization (WHO) 2022 classification criteria for Pediatric Tumors. Two groups were defined: (1) histologically confirmed PTLD, and (2) ‘indeterminate PTLD’ if criteria were not entirely met.Results: During the inclusion period, 111 patients underwent LT. Histology review confirmed PTLD in 13 patients (11.7%) while 3 patients were included in the ‘indeterminate’ group. The most common subtype was non‐destructive PTLD (6/13), followed by monomorphic (4/13) and polymorphic PTLD (3/13). Hypermetabolism on whole body (18F) fluorodeoxyglucose PET/CT helped define adequate biopsy location in 11/13 patients. Three patients with monomorphic PTLD also showed low‐grade PTLD subtypes in other biopsy sites. Nine patients received mTOR inhibitors after diagnosis, either as monotherapy or in combination with calcineurin inhibitors, without major side effects.Conclusions: The detailed analysis of our series of pediatric LT patients with PTLD allowed for the development of a diagnostic and management algorithm, now applied at our institution. Spatial and temporal heterogeneity argues in favor of multiple and, if necessary, repeated biopsies at different sites.
- 16 April 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (3) , e70060
Open AccessMeeting the Challenges of Post‐Transplant Lymphoproliferative Disorders After Liver Transplantation in Children: A Proposed Diagnostic and Management Algorithm
Background: Post‐transplant lymphoproliferative disorders (PTLD) may significantly impair outcomes in children after solid organ transplantation (SOT). Diagnosis and treatment may be challenging. We analyze a representative pediatric liver transplant (LT) cohort in light of these challenges.Methods: Pediatric LT recipients monitored by the Swiss Pediatric Liver Center from 2009 to 2021 with a suspicion of Epstein–Barr virus (EBV) driven PTLD were included. All cases were retrospectively reviewed using the World Health Organization (WHO) 2022 classification criteria for Pediatric Tumors. Two groups were defined: (1) histologically confirmed PTLD, and (2) ‘indeterminate PTLD’ if criteria were not entirely met.Results: During the inclusion period, 111 patients underwent LT. Histology review confirmed PTLD in 13 patients (11.7%) while 3 patients were included in the ‘indeterminate’ group. The most common subtype was non‐destructive PTLD (6/13), followed by monomorphic (4/13) and polymorphic PTLD (3/13). Hypermetabolism on whole body (18F) fluorodeoxyglucose PET/CT helped define adequate biopsy location in 11/13 patients. Three patients with monomorphic PTLD also showed low‐grade PTLD subtypes in other biopsy sites. Nine patients received mTOR inhibitors after diagnosis, either as monotherapy or in combination with calcineurin inhibitors, without major side effects.Conclusions: The detailed analysis of our series of pediatric LT patients with PTLD allowed for the development of a diagnostic and management algorithm, now applied at our institution. Spatial and temporal heterogeneity argues in favor of multiple and, if necessary, repeated biopsies at different sites.
- Open Access
- 18 July 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (1) , 170-180
Long-term persistence of seroprotection against measles following measles-mumps-rubella vaccination administered before and after pediatric liver transplantation
- 18 July 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (1) , 170-180
Open AccessLong-term persistence of seroprotection against measles following measles-mumps-rubella vaccination administered before and after pediatric liver transplantation
- Open Access
- 29 May 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 81 (5) , 862-871
Plasma immune signatures can predict rejection-free survival in the first year after pediatric liver transplantation
- 29 May 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 81 (5) , 862-871
Open AccessPlasma immune signatures can predict rejection-free survival in the first year after pediatric liver transplantation
- Open Access
- 30 January 2024
- Published by Elsevier in JHEP Reports
- Vol. 6 (3) , 101024
Corrigendum to “Expert management of congenital portosystemic shunts and their complications” [JHEP Reports 6 (2024)]
- 30 January 2024
- Published by Elsevier in JHEP Reports
- Vol. 6 (3) , 101024
Open AccessCorrigendum to “Expert management of congenital portosystemic shunts and their complications” [JHEP Reports 6 (2024)]
- Open Access
- 17 January 2024
- Published by Wiley in Liver International
- Vol. 44 (3) , 811-822
Natural history of Wolcott‐Rallison syndrome: A systematic review and follow‐up study
Background and Aims: To systematically review the literature for reports on Wolcott‐Rallison syndrome, focusing on the spectrum and natural history, genotype‐phenotype correlations, patient and native liver survival, and long‐term outcomes. Methods: PubMed, Livio, Google Scholar, Scopus and Web of Science databases were searched. Data on genotype, phenotype, therapy, cause of death and follow‐up were extracted. Survival and correlation analyses were performed. Results: Sixty‐two studies with 159 patients met the inclusion criteria and additional 30 WRS individuals were collected by personal contact. The median age of presentation was 2.5 months (IQR 2) and of death was 36 months (IQR 50.75). The most frequent clinical feature was neonatal diabetes in all patients, followed by liver impairment in 73%, impaired growth in 72%, skeletal abnormalities in 59.8%, the nervous system in 37.6%, the kidney in 35.4%, insufficient haematopoiesis in 34.4%, hypothyroidism in 14.8% and exocrine pancreas insufficiency in 10.6%. Episodes of acute liver failure were frequently reported. Liver transplantation was performed in six, combined liver‐pancreas in one and combined liver‐pancreas‐kidney transplantation in two individuals. Patient survival was significantly better in the transplant cohort ( p = .0057). One‐, five‐ and ten‐year patient survival rates were 89.4%, 65.5% and 53.1%, respectively. Liver failure was reported as the leading cause of death in 17.9% of cases. Overall survival was better in individuals with missense mutations ( p = .013). Conclusion: Wolcott‐Rallison syndrome has variable clinical courses. Overall survival is better in individuals with missense mutations. Liver‐ or multi‐organ transplantation is a feasible treatment option to improve survival.
- 17 January 2024
- Published by Wiley in Liver International
- Vol. 44 (3) , 811-822
Open AccessNatural history of Wolcott‐Rallison syndrome: A systematic review and follow‐up study
Background and Aims: To systematically review the literature for reports on Wolcott‐Rallison syndrome, focusing on the spectrum and natural history, genotype‐phenotype correlations, patient and native liver survival, and long‐term outcomes. Methods: PubMed, Livio, Google Scholar, Scopus and Web of Science databases were searched. Data on genotype, phenotype, therapy, cause of death and follow‐up were extracted. Survival and correlation analyses were performed. Results: Sixty‐two studies with 159 patients met the inclusion criteria and additional 30 WRS individuals were collected by personal contact. The median age of presentation was 2.5 months (IQR 2) and of death was 36 months (IQR 50.75). The most frequent clinical feature was neonatal diabetes in all patients, followed by liver impairment in 73%, impaired growth in 72%, skeletal abnormalities in 59.8%, the nervous system in 37.6%, the kidney in 35.4%, insufficient haematopoiesis in 34.4%, hypothyroidism in 14.8% and exocrine pancreas insufficiency in 10.6%. Episodes of acute liver failure were frequently reported. Liver transplantation was performed in six, combined liver‐pancreas in one and combined liver‐pancreas‐kidney transplantation in two individuals. Patient survival was significantly better in the transplant cohort ( p = .0057). One‐, five‐ and ten‐year patient survival rates were 89.4%, 65.5% and 53.1%, respectively. Liver failure was reported as the leading cause of death in 17.9% of cases. Overall survival was better in individuals with missense mutations ( p = .013). Conclusion: Wolcott‐Rallison syndrome has variable clinical courses. Overall survival is better in individuals with missense mutations. Liver‐ or multi‐organ transplantation is a feasible treatment option to improve survival.